Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer

NCT05249127 is registered in ClinicalTrials.gov with Clarity Pharmaceuticals Ltd as lead sponsor.

NCT NCT05249127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05249127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate Cancer
Lead sponsor
Clarity Pharmaceuticals Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
April 11, 2022
Completion date
August 8, 2023
Enrollment
52 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

biochemical recurrence of malignant neoplasm of prostate